INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Intellia Therapeutics, Inc. regarding breaches of fiduciary duties by the board of directors following a class action complaint related to the company's Phase 1/2 study and subsequent reorganization [1][2][3] Group 1: Legal Investigation - A class action complaint was filed against Intellia on February 11, 2025, with a class period from July 30, 2024, to January 8, 2025 [1] - The investigation focuses on whether Intellia's board of directors failed to disclose critical information regarding the demand for viral-based editing and the inefficiency of the NTLA-3001 program [2] Group 2: Company Reorganization - On January 9, 2025, Intellia announced a reorganization, halting all NTLA-3001 research and reducing its workforce by 27% in 2025 [3] - The decision to discontinue NTLA-3001 was part of a broader strategy to focus resources on other pharmaceutical developments [3] Group 3: Stock Price Impact - Following the announcement of the reorganization, Intellia's stock price dropped from $12.02 per share on January 8, 2025, to$10.20 per share on January 10, 2025 [4]